RegeneRx has developed Tβ4 as an active pharmaceutical ingredient to allow usage in drugs and has completed several clinical trials on various diseases for which the medicine is efficacious.
In particular, it has received Orphan Drug Designation from the US FDA on epidermolysis bullosa and neurotrophic keratopathy that are rare diseases.
We are using the novel peptide component (Tβ4) that hasn’t been developed as a treatment yet for a new growth power business through collaboration with RegeneRx Biopharmaceuticals, Inc. which is the new drug development company in the US.
In particular, it has received Orphan Drug Designation from the US FDA on epidermolysis bullosa and neurotrophic keratopathy that are rare diseases.
We are using the novel peptide component (Tβ4) that hasn’t been developed as a treatment yet for a new growth power business through collaboration with RegeneRx Biopharmaceuticals, Inc. which is the new drug development company in the US.